May 16th 2024
The FDA accelerated approval of tarlatamab makes it the first bispecific T-cell engager therapy for a major solid tumor.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Antitumor Activity Is Reported for Lurbinectedin in 4 Molecular Subtypes of SCLC
June 2nd 2023Lurbinectedin yielded a value of 6.52 nM on the key pharmacological efficacy variable IC50, according to a poster presented at the 2023 Annual Meeting of the American Association for Cancer Research
Read More
Radiation Plus Immune Checkpoint Blockade May Be an Alternative Option in SCLC
April 18th 2023In an interview, Ashish Saxena, MD, discussed the benefit of radiation for the treatment of small cell lung cancer, combining radiation with immune checkpoint blockade treatments, and the next steps for the space.
Read More
Room to Grow in the Small Cell Lung Cancer Treatment Landscape
April 10th 2023In an interview with Targeted Oncology, Nitika Sharma, MD, discussed frontline treatment options for small cell lung cancer and data supporting their use. Sharma also discussed ongoing clinical trials that may bring new therapies in the near future.
Read More
Sculptor Study Begins Enrolling Patients With Small Cell Lung Cancer
January 9th 2023Patients with small cell lung cancer will receive diagnostic and post-progression tumor tissue profiling, plasma ctDNA biomarker profiling, standard of care therapy, and disease surveillance in the Sculptor study.
Read More
Trilaciclib Shows Potential to Lower Chemotherapy-Induced Myelosuppression Episodes in ES-SCLC
November 18th 2022Real-world evidence from Florida Cancer Specialists & Research Institute shows that trilaciclib may reduce the chance of chemotherapy-induced myelosuppression events in patients with extensive-stage small cell lung cancer.
Read More
Episode 10B: Impact of Trilaciclib on Chemotherapy Induced Myelosuppression (CIM) in ES-SCLC
October 28th 2022In this companion article, Dr Mark Socinski provides insights into the use of trilaciclib for the management of chemotherapy-induced myelosuppression in patients being treated for extensive -stage small cell lung cancer.
Watch